Skip to content

Study · Systematic review · 2025

11 results

The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.

Ala M, Moheb Aleaba M

Journal of endocrinological investigation30 Sept 2024Cited by 4 (Europe PMC)

PMID39347905 (opens in a new tab)DOI10.1007/s40618-024-02459-3 (opens in a new tab)PepBankPUB-39347905
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of clinical trials, subcutaneous semaglutide lowered systolic blood pressure versus placebo (WMD -3.71 mmHg).

    In plain wordsAcross trials, semaglutide injections lowered systolic blood pressure more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    WMD systolic BP
    −3.71 mmHg
    pooled

    Source sentences

    Summary
    Subcutaneous semaglutide significantly decreased both systolic (WMD - 3.71 mmHg, 95% CI (-4.29, -3.13)
    1 context sentence
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of clinical trials, subcutaneous semaglutide lowered diastolic blood pressure versus placebo (WMD -1.10 mmHg).

    In plain wordsAcross trials, semaglutide injections lowered diastolic blood pressure more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    WMD diastolic BP
    −1.1 mmHg
    pooled

    Source sentences

    Summary
    Subcutaneous semaglutide significantly decreased both systolic
    2 context sentences
    Summary · context
    and diastolic (WMD - 1.10 mmHg, 95% CI (-1.58, -0.63), I2: 69.7%) blood pressure.
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  3. 03HumanSystematic reviewEfficacy outcome

    In subgroup analyses, the blood pressure-lowering effect of subcutaneous semaglutide was greater in patients without diabetes.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger in people without diabetes.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect in patients without diabetes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among patients without diabetes
    1 context sentence
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  4. 04HumanSystematic reviewEfficacy outcome

    In subgroup analyses, the blood pressure-lowering effect of subcutaneous semaglutide was greater in patients with lower baseline HbA1c.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger in people with lower starting HbA1c.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect by baseline HbA1c
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    lower baseline hemoglobin A1c (HbA1c)
    2 context sentences
    Summary · context
    Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  5. 05HumanSystematic reviewEfficacy outcome

    In subgroup analyses, the blood pressure-lowering effect of subcutaneous semaglutide was greater in patients with baseline BMI above 35 kg/m2.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger in people with a starting BMI above 35.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect by baseline BMI
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    body mass index (BMI) greater than 35 kg/m2
    2 context sentences
    Summary · context
    Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  6. 06HumanSystematic reviewEfficacy outcome

    In subgroup analyses, the blood pressure-lowering effect of subcutaneous semaglutide was greater at doses above 1 mg/week.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger at doses above 1 mg a week.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect by semaglutide dose
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    dose of semaglutide more than 1 mg/week
    2 context sentences
    Summary · context
    Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  7. 07HumanSystematic reviewEfficacy outcome

    In subgroup analyses, the blood pressure-lowering effect of subcutaneous semaglutide was greater in patients with baseline systolic blood pressure of 130 mmHg or less.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger in people whose starting systolic pressure was 130 mmHg or lower.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect by baseline systolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    baseline systolic blood pressure equal or less than 130 mmHg
    2 context sentences
    Summary · context
    Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  8. 08HumanSystematic reviewEfficacy outcome

    In subgroup analyses, the blood pressure-lowering effect of subcutaneous semaglutide was greater in patients with weight loss above 10 kg.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger in people who lost more than 10 kg.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect by weight loss
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    weight loss greater than 10 kg
    2 context sentences
    Summary · context
    Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  9. 09HumanSystematic reviewEfficacy outcome

    In subgroup analyses, the blood pressure-lowering effect of subcutaneous semaglutide was greater in patients with BMI reduction above 3 kg/m2.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger in people whose BMI fell by more than 3 points.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect by BMI reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    BMI reduction greater than 3 kg/m2
    2 context sentences
    Summary · context
    Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  10. 10HumanSystematic reviewEfficacy outcome

    In subgroup analysis, a treatment length of 50 to 100 weeks was associated with a greater blood pressure-lowering effect of subcutaneous semaglutide.

    In plain wordsThe blood pressure drop with semaglutide injections was bigger with 50 to 100 weeks of treatment.

    Peptide
    Semaglutide
    Outcome
    MixedBlood pressure effect by treatment length
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In addition, a treatment length of 50 to 100 weeks was associated with greater blood pressure-lowering effects in subgroup analysis.
    1 context sentence
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.
  11. 11HumanSystematic reviewEfficacy outcome

    In meta-regression, placebo-adjusted weight change was independently correlated with the effect of subcutaneous semaglutide on systolic and diastolic blood pressure.

    In plain wordsAcross trials, the placebo-adjusted weight change was linked to the blood pressure effect of semaglutide injections.

    Peptide
    Semaglutide
    Outcome
    Not applicableMeta-regression of blood pressure effect on weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After adjusting for other factors, meta-regression revealed that placebo-adjusted weight change was independently correlated with the effect of semaglutide on systolic and diastolic blood pressure.
    1 context sentence
    Summary · context
    Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.